Biocartis Group Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Herman Verrelst

Chief executive officer

€495.1k

Total compensation

CEO salary percentage	75.7%
CEO tenure	5.2yrs
CEO ownership	n/a
Management average tenure	5.2yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Herman Verrelst's remuneration changed compared to Biocartis Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2022	n/a	n/a	-€63m
Mar 31 2022	n/a	n/a	-€67m
Dec 31 2021	€495k	€375k	-€71m
Sep 30 2021	n/a	n/a	-€70m
Jun 30 2021	n/a	n/a	-€69m
Mar 31 2021	n/a	n/a	-€66m
Dec 31 2020	€502k	€375k	-€63m
Sep 30 2020	n/a	n/a	-€64m
Jun 30 2020	n/a	n/a	-€66m
Mar 31 2020	n/a	n/a	-€65m
Dec 31 2019	€448k	€375k	-€64m
Sep 30 2019	n/a	n/a	-€60m
Jun 30 2019	n/a	n/a	-€56m
Mar 31 2019	n/a	n/a	-€52m
Dec 31 2018	€510k	€375k	-€48m
Sep 30 2018	n/a	n/a	-€44m
Jun 30 2018	n/a	n/a	-€40m
Mar 31 2018	n/a	n/a	-€41m
Dec 31 2017	€232k	€137k	-€42m

Compensation vs Market: Herman's total compensation ($USD492.25K) is above average for companies of similar size in the UK market ($USD348.41K).

Compensation vs Earnings: Herman's compensation has been consistent with company performance over the past year.

CEO

Herman Verrelst (48 yo)

5.2yrs

Tenure

€495,058

Compensation

Mr. Herman Verrelst serves as Director at FOx Diagnostics. He has been Chief Executive Officer of Biocartis Group NV since August 31, 2017. Mr. Verrelst served as the President of the Board at FOx Diagnost...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Herman Verrelst	CEO & Executive Director	5.2yrs	€495.06k	no data
Jean-Marc Roelandt	Chief Financial Officer	2.5yrs	no data	no data
Piet Houwen	Chief Operating Officer	3.5yrs	no data	no data
Benoit Devogelaere	Chief Technology Officer	4.8yrs	no data	no data
Geert Maertens	Chairman of Scientific Advisory Board & Chief Scientific Officer	no data	no data	no data
Renate Degrave	Head of IR & Corporate Communications	no data	no data	no data
Susy Spruyt	Head of People & Organization	7.8yrs	no data	no data
Erwin Sablon	Head of R&D and Alliance Management	10.2yrs	no data	no data
Reginald Van Genechten	Head of Manufacturing & Supply Chain	6.6yrs	no data	no data
Dirk Zimmermann	Global Head of Pharma Collaborations & Partnering	3.4yrs	no data	no data
Erik Vossenaar	Vice President of Business Development	6.8yrs	no data	no data

5.2yrs

Average Tenure

54yo

Average Age

Experienced Management: BCARTB's management team is seasoned and experienced (5.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Herman Verrelst	CEO & Executive Director	5.1yrs	€495.06k	no data
Geert Maertens	Chairman of Scientific Advisory Board & Chief Scientific Officer	no data	no data	no data
Christian Reinaudo	Independent Chairman of the Board	4.4yrs	€81.00k	no data
Jean-Louis Vincent	Member of Scientific Advisory Board	no data	no data	no data
Ann-Christine Sundell	Non Executive Independent Director	4.8yrs	€43.50k	no data
Pasi Janne	Member of Scientific Advisory Board	no data	no data	no data
Alberto Bardelli	Member of Scientific Advisory Board	no data	no data	no data
Eric Cutsem	Member of Scientific Advisory Board	no data	no data	no data
Roald Borré	Non-Executive Director	8.8yrs	€38.50k	no data
Josep Tabernero	Member of Scientific Advisory Board	no data	no data	no data
Luc Gijsens	Non-Executive Independent Director	4.8yrs	€46.00k	no data
Michael Press	Member of Scientific Advisory Board	no data	no data	no data

4.8yrs

Average Tenure

58yo

Average Age

Experienced Board: BCARTB's board of directors are considered experienced (4.8 years average tenure).

Biocartis Group Management

Management criteria checks 3/4

Key information

Recent management updates

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Insufficient new directors

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Insufficient new directors

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Insufficient new directors

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age